Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine Versus Placebo in Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male/Female outpatients 18 years of age with chronic low back pain~* Females of child bearing potential must test negative on a pregnancy test at visit 1.~Exclusion Criteria:~* Have a serious or unstable diseases of the heart or blood vessels, liver, kidney, lungs, or blood-related illness~* Problems with decreased blood flow to arms and legs (peripheral vascular disease), or other medical conditions~* Psychiatric conditions that, in the opinion of the investigator, would affect your participation or be likely to lead to hospitalization during the course of the study~* Have acute liver injury (such as hepatitis) or severe cirrhosis~* Have had previous exposure to duloxetine~* Have a body mass index (BMI) over 40~* Have a major depressive disorder~* Require daily narcotics~* Have suicidal risk~* Have a presence of any factors/conditions, medical or other, that in the judgment of the investigator may interfere with performance of study outcome measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): 30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
- Placebo (Type: PLACEBO_COMPARATOR): every day (QD), by mouth (PO), 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).